Faslodex 유럽 연합 - 덴마크어 - EMA (European Medicines Agency)

faslodex

astrazeneca ab - fulvestrant - bryst neoplasmer - endokrine terapi, anti-østrogener - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. i præ - eller perimenopausal kvinder, kombinationen behandling med palbociclib bør kombineres med en luteiniserende hormon releasing hormon (lhrh) agonist.

Fulvestrant Mylan 유럽 연합 - 덴마크어 - EMA (European Medicines Agency)

fulvestrant mylan

mylan pharmaceuticals limited - fulvestrant - bryst neoplasmer - endokrine terapi - fulvestrant er indiceret til behandling af østrogen receptor positiv, lokalt fremskreden eller metastatisk brystkræft hos postmenopausale kvinder:ikke tidligere behandlet med endokrin terapi, orwith disease, tilbagefald eller efter adjuverende anti-østrogen behandling eller af sygdomsprogression på antiøstrogen terapi.

Latiotim 50 mikrog/ml+5 mg/ml øjendråber, opløsning 덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

latiotim 50 mikrog/ml+5 mg/ml øjendråber, opløsning

sandoz a/s - latanoprost, timololmaleat - øjendråber, opløsning - 50 mikrog/ml+5 mg/ml

Calcium-Sandoz 500 mg brusetabletter 덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

calcium-sandoz 500 mg brusetabletter

sandoz a/s - calciumcarbonat, calciumlactogluconat - brusetabletter - 500 mg